ClinicalTrials.gg
RecruitingNCT07761845Updated Aug 18, 2026

Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for Mortality of Patients With Burn Injuries

An observational study in Burn Injuries, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Ain Shams University · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.

Read the detailed description

The aim of this study is to evaluate the prognostic utility of the red cell distribution width/albumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.

Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.

After consent, patients' characteristics (age, sex, weight), clinical parameters (total burn surface area, Abbreviated Burn Severity Index), and comorbidities will be recorded.

  1. Emergency Department (ED) management (Arrival and Initial Stabilization)

    • Primary survey (ATLS principles): Immediate stabilization of Airway, Breathing, Circulation, Disability, Exposure (ABCDE).
    • Urinary catheter insertion to monitor urine output for proper resuscitation.
    • TBSA will be estimated using the Rule of Nines
    • All patients will be treated during the first 24 hours after burn injury guided by the Parkland Formula.
  2. In-Hospital Resuscitation (0-72 h)

    • Hemodynamic monitoring: ECG, pulse oximetry, respiratory rate, temperature, non-invasive blood pressure, arterial line if unstable, and central venous pressure.
    • Transition to Day 2 (24-48 h post-burn): Continue Lactated Ringer's and consider colloid therapy (5% albumin or plasma) after 24 h to maintain oncotic pressure and reduce crystalloid load.
    • Fluid adjustments according to urine output, mean arterial pressure with target MAP (≥65 mmHg), lactate clearance, and base deficit.

    Laboratory and calculation:

    On admission to ED, an arterial blood gas (ABG) sample will be collected to calculate base deficit (BD) and lactate level.

    Simultaneously, venous blood will be drawn for C-reactive protein (CRP) and serum albumin, CBC, serum urea, creatinine, AST, ALT, and electrolytes (Na+, K+, Mg+) estimation.

    Red Cell Distribution Width/Albumin will be calculated as:

    ((RDW (Standard Deviation of Red Blood Cell Volume / Mean Corpuscular Volume) × 100%.) / albumin (g/L)) from admission labs.

    Serial: Lactate/Base Deficit at 6 hr, 12 hr, 24 hr as a monitor for proper resuscitation Calculation of Severity Scores

    • R-Baux score: Age (years) + %TBSA + (17 × inhalation injury [yes=1, no=0])
    • Abbreviated Burn Severity Index (ABSI): The ABSI includes five parameters: sex, age category, %TBSA, presence of full-thickness burns, and inhalation injury. Each parameter is assigned weighted points, and the total ABSI score is associated with graded survival probabilities.

    Both scores will be calculated on admission and compared with admission (RDW/albumin) ratio to assess relative and incremental predictive value for 30-day mortality.

    Supportive care:

    • Early enteral nutrition, proper multimodal analgesia (paracetamol 1gm/8hr, nalbuphine 0.1mg/kg if VAS score>4), IV proton pump inhibitor to guard against curling ulcer, prophylactic anticoagulation to guard against DVT.
    • Vasopressors (norepinephrine) only after adequate fluid resuscitation guided by UOP, lactate and BD if MAP below 65 mmHg.

      3 - Post-Resuscitation and Definitive Management Protocol (After 72 h) Hemodynamic stabilization (post-resuscitation phase) Transition from resuscitation fluids to maintenance fluids. Avoid "fluid creep" (excess positive balance leading to pulmonary edema, abdominal compartment). → cautious use of diuretics to mobilize edema.

    Maintain: MAP ≥65 mmHg, urine output ≥0.5 mL/kg/h. Ongoing ventilatory support if required; lung-protective strategy for ARDS. Weaning as early as possible.

    Infection prevention and sepsis monitoring

    • Daily wound assessment for signs of infection, weekly or targeted wound/blood cultures and antibiotics only if infection is suspected/proven (not prophylactic).

    Wound care and surgical management

    • Regular dressing, use of negative-pressure wound therapy when indicated.
    • Early excision and grafting after 72 hr. Pain and sedation control
    • Multimodal analgesia, pre-procedure analgesia for dressing/grafting and long-term psychological and pain management.

    Rehabilitation and functional recovery • Early physiotherapy, occupational therapy for daily living skills and psychosocial support for patient and family.

    Criteria for transfer to ward • Hemodynamically stable, off vasopressors.

    • Stable oxygenation without advanced ventilatory support.
    • Tolerating enteral feeding.
    • Wounds coverage completed or adequately covered with new TBSA% below 20%.
    • Patients will be followed for 30 days at Ain Shams University burn unit. Measured outcomes

    Primary outcome:

    To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30-day hospital mortality in burn patients.

    Secondary outcomes:

    To determine the correlation between Red Cell Distribution Width/Albumin with:

    • ICU length of stay
    • Hospital length of stay
    • Requirements of inotropes or vasopressors
    • Duration of mechanical ventilation
    • To compare Red Cell Distribution Width/albumin ratio with R-Baux score as a predictor of mortality in burn patients.
02

Conditions studied

  • Burn Injuries

Browse trials for

Keywords

  • burn
  • mortality
  • albumin
  • Red Cell Distribution Width
03

In context

Burns

905 studies on the registry are indexed under Burns; 164 are open to participants now.

This study's planned enrollment of 30 is below the median of 64 across 163 observational studies indexed under Burns.

Browse Burns studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients presenting with acute thermal injuries will be screened based on inclusion/exclusion criteria.

After consent, Patients' characteristics (age, sex, weight), clinical parameters (Total burn surface area, Abbreviated burn severity index), and comorbidities will be recorded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years.
  • Both sexes.
  • Patients with burn injuries (%TBSA >20%).
  • Availability of complete laboratory data (RDW, albumin) on admission.
  • Admission to ICU within 24 hours of burn injury.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years.
  • Patients with chronic hematologic disease.
  • Pre-existing liver disease.
  • Nephrotic syndrome.
  • patients on chemotherapy.
  • Patients with incomplete or missing lab records.
  • Pregnant females.
  • Patient or guardian refusal.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • • Patients with burn injuries (%TBSA >20%)

    each patient will be followed for 30 days for mortality prediction

06

What researchers measure

Primary outcomes

  1. mortality in burn patients

    To determine the correlation between Red Cell Distribution Width/Albumin on admission and 30 days hospital mortality in burn patients.

    Time frame: 30 days

Secondary outcomes

  1. ICU length of stay

    To determine the correlation between Red Cell Distribution Width/Albumin with o ICU length of stay

    Time frame: 30 days

  2. To compare RDW/albumin ratio with Revised Baux score as a predictor of mortality in burn patient.

    Revised Baux score = (percent body surface burned) + (patient's age) + 17 (if inhalational injury is present) A higher Revised Baux score generally indicates a higher risk of mortality, with scores over 140 unsurvivable .

    Time frame: 30 days

  3. Requirements of inotropes or vasopressors

    To determine the correlation between Red Cell Distribution Width/Albumin with o Requirements of inotropes or vasopressors

    Time frame: 30 days

  4. Duration of mechanical ventilation

    To determine the correlation between Red Cell Distribution Width/Albumin with o Duration of mechanical ventilation

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the study results will be made available upon reasonable request from qualified researchers

Supporting information: Study protocol

Time frame: Within 6:12 months

Access criteria: Access will be granted to researchers who submit a methodologically sound proposal to the principal investigator. Requests should be directed to g19-29502090100101@med.asu.edu.eg

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

Of 56 non-industry observational studies under Burns, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's planned 6 months is below that.

Counting every sponsor, half of 68 studies reached it within 24 months; a quarter within 14 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2026
First posted
Aug 12, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07761845
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Aug 1, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

Ahlam M abdelnaby. study principal investigator, MBBCH, MSc .
Contact
g19-29502090100101@med.asu.edu.eg
+201120327604
Sara H Saleh, MD
Contact
+201001584305
Adel M Fahmy Shenouda, MD
study chair · Department of Anesthesia, Intensive care and pain management, Faculty of Medicine, Ain Shams University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion